Metro Toronto
Convention Centre
South Building
222 Bremner Blvd
Toronto, ON M5V 2W6
Community Cardiology Preliminary Program
Saturday, October 22
08:00 - 13:00
YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST
RÉTROSPECTIVE DE L'ANNÉE EN CARDIOLOGIE
CLINIQUE
Co-Chairs: Milan Gupta
David Bewick
Randall Williams
Target Audience:
Community-based cardiologists wanting comprehensive and timely information to apply to their practice. This comprehensive educational program will complement the CCC experience for all who attend! Join your colleagues in a "Year in Review" and an update about major areas of clinical cardiology.
• Put recent clinical trials into context
• Review practice changing guidelines: latest management recommendations
• Address changing concepts in cardiology
08:30 - 09:30
YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST -
HEART FAILURE
RÉTROSPECTIVE DE L'ANNÉE EN CARDIOLOGIE CLINIQUE - INSUFFISANCE CARDIAQUE
Aldosterone Antagonists in Mild-to-Moderate Heart Failure Malcolm Arnold
London, Ontario
The Role of Device Therapy in Mild-to-Moderate Heart Failure Anthony Tang
Ottawa, Ontario
09:30 - 10:30
YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST -
STROKE PREVENTION IN ATRIAL FIBRILLATION
RÉTROSPECTIVE DE L'ANNÉE EN CARDIOLOGIE CLINIQUE - LA PRÉVENTION DES AVC DANS LES CAS DE FIBRILLATION AURICULAIRE
Recent Trials With Factor Xa Inhibitors Stuart Connolly
Hamilton, Ontario
Choices for Stroke Prevention: Putting Things into Perspective Brent Mitchell
Calgary, Alberta
11:00 - 12:00
YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST -
CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR RISK
RÉTROSPECTIVE DE L'ANNÉE EN CARIDIOLOGIE CLINIQUE - NÉPHROPATHIE CHRONIQUE ET RISQUE CARDIOVASCULAIRE
Prevention of Cardiovascular Events in Patients with Chronic Kidney Disease Milan Gupta
Brampton, Ontario
Prevention of Contrast Nephropathy Rodney Zimmerman
Regina, Saskatchewan
12:00 - 13:00
YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST -
CONTROVERSIES IN CARDIOLOGY
RÉTROSPECTIVE DE L'ANNÉE EN CARDIOLOGIE CLINIQUE - CONTROVERSES EN CARDIOLOGIE
Radiation Exposure and Cardiovascular Imaging Rob Beanlands
Ottawa, Ontario
2009 Lipid Guidelines Revisited: What is the Current Role of CRP? Jacques Genest
Montréal, Québec
13:00 - 16:00
Accredited Symposium CONTROVERSIES IN CORONARY INTERVENTIONS: THE ANNUAL INTERVENTIONAL CARDIOLOGY WORKSHOP
CONTROVERSES DANS LES INTERVENTIONS CORONARIENNES: L'ATELIER ANNUEL CANADIEN DE LA CARDIOLOGIE INTERVENTIONNELLE This accredited symposium was co-developed with the Canadian Cardiovascular Society and Medtronic of Canada, and was planned to ensure the evidence presented is valid, objective and balanced.
This symposium will use real-world case histories, and case examples to underscore different, and often controversial interventional cardiology techniques to treat patients. The objective of this symposium will for participants to gain a clear understanding and appreciation for different perspectives in dealing with complexity in daily interventional cases: that there is no single approach, rather that there is an armamentarium at the disposal of the Interventional Cardiologist.
Target Audience:
Interventional cardiologists
18:00 - 21:00
Accredited Symposium EXPERT OPINIONS: ADVANCES IN CARDIOLOGY
OPINIONS D’EXPERTS : PROGRÈS EN CARDIOLOGIE This accredited symposium was co-developed with the Canadian Cardiovascular Society, AstraZeneca and Servier Canada, and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Subodh Verma
Over the years, randomized clinical trials for drugs treating cardiovascular disease have not always included a wide spectrum of patients. Increasingly, clinicians are hoping to understand the spectrum of cardiovascular risks that affect these special patients. This symposium will focus on the following groups to better understand the varying risks for them:
Visible minorities
Elderly
Women
Patients with renal impairment.
The symposium will also feature a keynote presentation on the future of wireless medicine. This section will focus on the promise of wireless medicine with a special focus on wireless devices and their respective cardiac apps. Physicians will also have an opportunity to test drive some of the new cardiac apps that are destined to change the practice of medicine. In a look forward to the future, this symposium will also educate delegates on the latest developments in the use of wireless devices in cardiology.
Accredited Symposium ANTICOAGULANT SAFETY: BLEEDING AND BEYOND
ANTICOAGULANT SANS RISQUE : SAIGNEMENT ET AUTRE This accredited symposium was co-developed with the Canadian Cardiovascular Society, Bristol Myers Squibb and Pfizer Canada and was planned to ensure the evidence presented is valid, objective and balanced.
This symposium aims to provide an overview of the efficacy & safety of the anticoagulants used for stroke prevention in patients with Atrial Fibrillation while also reviewing the bleeding profile of these medications. It will also give participants the opportunity to discuss potential drug interactions related to anticoagulants while also reviewing optimal treatment options for patients with renal impairment. The symposium will also review risk stratification and risk assessment tools. It will also expose participants to the recent clinical trials of various antithrombotic treatment options in Atrial Fibrillation. Furthermore, participants will be exposed to discussions with faculty via the touch pad technology.
Accredited Symposium NEW CONCEPTS IN ACUTE CORONARY SYNDROMES: BEYOND 2000 (XVII)
NOUVEAUX PRINCIPES SUR LE SYNDROME CORONARIEN AIGU : AU-DELÀ DE L'AN 2000 (XVII) This accredited symposium was co-developed with the Canadian Cardiovascular Society, University of Alberta, AstraZeneca Canada Inc. and Merck, and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Paul Armstrong
This program will be comprehensive and explore broad and novel concepts relating to the large cross section of patients with acute coronary syndromes (ACS). Specifically, it will evaluate the changing epidemiology of ACS, the impact of novel advances in molecular medicine and the extent to which these are clinically applicable. Insight into the key role of a systems-approach to the management of acute coronary disease will be emphasized. The implications of diabetes, sex differences, and the increasingly important consequences of bleeding in ACS will be discussed. The changing role of electrical devices as it applies to the spectrum of patients with acute coronary disease will be undertaken. Finally, the key role of a general internist in secondary prevention of acute cardiovascular disease will be provided. These topics will be brought to life with focused case presentations designed to enrich the audience's understanding of these clinically relevant topics.
CCC OPENING CEREMONIES AND HSFC LECTURE
CÉRÉMONIE D'OUVERTURE DU CONGRÈS ET CONFÉRENCE DE LA FMCC
Co-Chairs / Co-présidents: Rob Beanlands
Irfhan Rawji
Clyde Yancy
Chicago, Illinois
Northwestern University
18:00 - 21:00
Accredited Symposium HDL FORUM: NEW PROSPECTS FOR REDUCING CARDIOVASCULAR RISK
FORUM HDL : NOUVELLES PERSPECTIVES POUR LA RÉDUCTION DU RISQUE CARDIOVASCULAIRE This accredited symposium was co-developed with the Canadian Cardiovascular Society and Roche Canada, and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Jean-Claude Tardif
The 2011 HDL Forum will present the current and emerging evidence on HDL as a treatment target in the prevention and management of CVD. This symposium will be delivered by an international faculty and will focus on the impact of functional HDL including its potential role in the protection of the endothelium and in the modification of the underlying disease of atherosclerosis. Important completed and ongoing clinical trials in the field will be discussed.
Accredited Symposium WHEN THE HEART ASSAULTS THE BRAIN: PREVENTING STROKE IN ATRIAL FIBRILLATION
LORSQUE LE CŒUR S'EN PREND AU CERVEAU : LA PRÉVENTION DES AVC DANS LES CAS DE FIBRILLATION AURICULAIRE This accredited symposium was co-developed with the Canadian Cardiovascular Society and Boehringer Ingelheim (Canada) Ltd., and was planned to ensure the evidence presented is valid, objective and balanced.
Co-Chairs: Paul Dorian
Martin Green
This interactive symposium will provide participants with the opportunity to learn through real-life case studies, interactive presentations, and expert panel discussions. Topics will include:
Stroke in Atrial Fibrillation: A Neurologist's Perspective
Canadian Cardiovascular Society Guidelines in Atrial Fibrillation: Focus on Stroke Prevention
Randomized Clinical Trials With Alternatives to Warfarin: A Review of the Data
Participants will review stroke epidemiology, with a detailed look at cardioembolic stroke and its relationship to atrial fibrillation (AF).
There will be a discussion around risk stratification for stroke and bleeding in patients with AF, along with a review of the most recent Canadian Cardiovascular Society guidelines in AF. In addition, the most recent clinical trial results with new anticoagulants will be presented, explored, and contextualized in order to help clinicians understand how these new therapies fit into current practice.
Accredited Symposium THE COMMUNITY CARDIOLOGIST FORUM: GLOBAL ROUND TABLE ON SYMPTOMATIC CAD
LE FORUM COMMUNAUTAIRE DES CARDIOLOGUES : TABLE RONDE MONDIALE SUR LA MALADIE CORONARIENNE SYMPTOMATIQUE This accredited symposium was co-developed with the Canadian Cardiovascular Society and Servier Canada Inc. and was planned to ensure the evidence presented is valid, objective and balanced.
In 2011, an important new accredited symposium will be offered at CCC with a special focus on the clinical challenges faced by community cardiologists. For the first time, Canadian community cardiologists will take the stage with colleagues from other countries to share their experiences around an important community-based clinical challenge. For this first Global Round Table, the focus will be on treating symptomatic CAD. The most common presenting symptom for CAD is chest pain associated with angina. Heart rate reduction plays a central role in the management of patients with angina pectoris. Treating angina remains an important challenge for community cardiologists not only in Canada but around the world. The Global Round Table will allow for a group of Canadian community-based cardiologists to exchange with international colleagues on the best treatment strategies for treating patients with Symptomatic CAD. This accredited symposium will also provide Canadian community cardiologists with important insights on new treatment strategies for heart-rate lowering based on the direct clinical experience of their international colleagues.
Accredited Symposium CURRENT ISSUES IN THE MANAGEMENT OF ATRIAL
FIBRILLATION: A CASE BASED APPROACH
QUESTIONS D'ACTUALITÉ EN MATIÈRE DE GESTION DE LA FIBRILLATION AURICULAIRE : UNE APPROCHE AXÉE SUR L'ÉTUDE DE CAS This accredited symposium was co-developed with the Canadian Cardiovascular Society and sanofi-aventis and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Paul Dorian
A new study published in the Canadian Journal of Cardiology highlights the gaps in knowledge, skill and competencies of Canadian physicians caring for patients with atrial fibrillation (AF). Key findings of the study include: physicians reported being challenged by the need to individualize and constantly adjust each treatment, lacking the knowledge, skills and confidence to support their clinical judgments; that the use of rate or rhythm control in the management of AF remained unclear; lack of knowledge and confidence about new drugs and suboptimal knowledge of the CCS guidelines for management of patients with AF along with lack of confidence in their application. This symposium will employ a case-based approach to address these educational needs and provide a systematic and consistent approach to assessing and managing patients with AF. Experts will incorporate and explain recent changes to the 2010 CCS guidelines for the management of AF to help physicians and other healthcare professionals apply this knowledge to improve the care of their patients with AF.
Accredited Symposium ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH DIABETES INTEGRATED INTERVENTIONAL AND
PHARMACALOGIC STRATEGIES FOR IMPROVED OUTCOMES
SYNDROME CORONARIEN AIGU CHEZ LES PATIENTS ATTEINTS DE DIABÈTE — STRATÉGIES INTERVENTIONNELLES ET PHARMACOLOGIQUES INTÉGRÉES POUR AMÉLIORER LES RÉSULTATS CLINIQUES This accredited symposium was co-developed with the Canadian Cardiovascular Society, Eli Lilly Canada and Boehringer Ingelheim (Canada) Ltd. and was planned to ensure the evidence presented is valid, objective and balanced.
ACS is a major cause of morbidity and mortality in diabetes, a disease associated with accelerated atherosclerosis. Antiplatelet therapy is a key component of ACS management, along with PCI in carefully selected patients. However, clinicians must balance potency of antiplatelet therapy with the potential for increased bleeding or recurrent thromboembolic events, a decision complicated by variability in patient response and in platelet function, as well as diabetes-related complications and their frequently occurring coexisting disorders. This Interactive ShowCASE™ incorporates three distinct educational formats, each enhanced by a hand-held digital device, to provide current evidence-based best practices in this dynamic field.
Accredited Symposium CORONARY INTERVENTION WITHOUT ON-SITE SURGERY: THE CANADIAN MODEL
INTERVENTION CORONARIENNE SANS CHIRURGIE SUR PLACE : LE MODÈLE CANADIEN This accredited symposium was co-developed with the Canadian Cardiovascular Society, Cordis/ Johnson & Johnson and C.K. Hui Heart Centre, and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Neil Brass
Delivery of advanced cardiac procedures such as coronary angioplasty in a timely and expeditious manner is essential to the health of Canadians. There are however large rural and urban populations who do not have ready access to potentially lifesaving procedures due to the vast geography of the Canadian landscape. While coronary intervention has traditionally been viewed as a tertiary level service carried out in urban centres with on-site surgical facilities, there has been a growing number of centres across Canada establishing coronary angioplasty programs without on-site surgical back up to fill this need. These programs are at various stages of maturity from some in their infancy to those active for over a quarter century providing a paradigm for this model of service delivery. This symposium will be presented by the network of Canadian centres carrying out cardiac intervention without on-site cardiac surgery to highlight a facet of contemporary Canadian standard of practice unfamiliar to many practitioners. Topics will encompass organization of the programs and the type of local, regional and provincial issues encountered. Centres will detail their clinical experiences, results and outcomes. Specific clinical scenarios will be reviewed, such as management of complex cases and use of specialized equipment in the standalone setting as well as anticipation, avoidance and management of complications. The information provided will be summarized as a framework for policy considerations for setting up stand-alone angioplasty programmes across the country.
Accredited Symposium ACS CARE IN CANADA: AN EVOLVING PARADIGM
LA PRISE EN CHARGE DU SCA AU CANADA : UN PARADIGME EN ÉVOLUTION This accredited symposium was co-developed with the Canadian Cardiovascular Society and AstraZeneca Canada Inc. and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Shamir Mehta
The landscape of antiplatelet therapy is rapidly changing, with recent landmark trials providing critical efficacy and safety information on new and existing therapies for Acute Coronary Syndromes (ACS). Therefore, there is a clear need for contemporary perspectives by experts in this area, so healthcare practitioners delivering ACS care to Canadian patients can better interpret the role of all emerging agents, in order to optimize long-term patient outcomes. This symposium will aim to gain a better understanding of the mechanisms and profiles of antiplatelet therapies, in order to provide a foundation for exploring the future standard of care for treating ACS.
Accredited Symposium FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION: ASK THE EXPERT
PLEINS FEUX SUR LA PRÉVENTION DES AVC DANS LES CAS DE FIBRILLATION AURICULAIRE : CONSULTER LE SPÉCIALISTE This accredited symposium was co-developed with the Canadian Cardiovascular Society and Bayer Canada, and was planned to ensure the evidence presented is valid, objective and balanced.
Chair: Atul Verma
First approved in the 1950s, warfarin remains to this day the most widely prescribed anticoagulant in North America. Now, almost sixty years since its introduction, warfarin might soon be eclipsed by important and potentially practice-changing advances in medical science, offering physicians a new generation of agents that have already, and may continue, to prove safer and more effective for preventing stroke. This new era of oral anticoagulation therapy is arriving with much promise. Many questions are yet to be answered. How do they compare and contrast the totality of data from the landmark clinical trials-ROCKET-AF, RE-LY, ARISTOTLE, AVERROES and translate it to clinical practice? What role, if any, will warfarin still have for patients with good INR control? The accredited symposium Focus on SPAF: Ask the Expert, will seek to answer these questions and more. An international panel of experts will convene to present the results from these landmark trials and analyze this data. Canadian leaders treating stroke and atrial fibrillation will join them to determine what the implications will be for clinical practice in our country. And in the spirit of open dialogue, health care professionals from coast-to coast-to coast will join the symposium using telepresence technology to engage these world-renowned panelists and their Canadian colleagues with questions.
LIVE CASE DEMONSTRATIONS
CAS EN DIRECT
Percutaneous Coronary and Valvular Interventions
Interventions coronariennes et valvulaires percutanées
This session was co-developed with the Canadian Cardiovascular Society, St. Paul's Hospital Foundation and
Edwards Life Sciences, and was planned to ensure the evidence presented is valid, objective and balanced.
The program is a live demonstration of two cases transmitted from St. Paul's Hospital in Vancouver. The first case will describe the planning and realization of a procedure aiming at recanalization of a chronic total coronary occlusion (CTO). Novel techniques have greatly enhanced procedural success for this complex coronary lesion. The second case is a transcatheter aortic valve implantation (TAVI). TAVI has emerged as an interesting alternative to surgical aortic valve replacement in high risk patients with severe aortic stenosis.
The priority will be to engage the audience in the discussions. Participants will be able to view the cases and ask questions to the operating physicians and panel members during the procedures.
Co-Chairs: Josep Rodes-Cabau
John Webb
Learning Objectives:
At the conclusion of this workshop, participants will be able to:
discuss technological and pharmaceutical developments in the field of interventional cardiology;
develop new clinical approaches to coronary and valvular diseases using imaging and less invasive procedures
apply guidelines and understand new therapeutic strategies applicable in their clinical practice; and
assess the patient eligibility criteria for coronary and valvular procedures, potential complications, and patient management prior to and after the procedure.
Live Case 1: Transfemoral aortic valve implantation
Live Case 2: Chronic Total Coronary Occlusion
Panel Discussion and Q&A
Wednesday, October 26
07:00 - 09:00
Accredited Symposium EXPERT OPINIONS: CURRENT ISSUES IN CARDIOLOGY
OPINIONS D’EXPERTS : ENJEUX ACTUELS EN CARDIOLOGIE This accredited symposium was co-developed with the Canadian Cardiovascular Society, AstraZeneca, Merck Canada and Servier Canada Inc. and was planned to ensure the evidence presented is valid, objective and balanced.
Co-Chairs: Jean Rouleau
Subodh Verma
This symposium will feature a debate-format discussion on the intersection between dyslipidemia and renal disease and discuss emerging risk factors in CKD patients. The symposium will also focus on heart rate as a potential risk factor for cardiovascular disease - is it in the league of blood pressure & LDL? Finally, there will be a translational feature – looking at emerging science for 2011.
Atherosclerosis, Basic Vascular
Ischemic Heart Disease, ACS, PCI, Stroke
Pediatrics and Congenital Heart Disease
Heart Failure, Heart Function, Cardiomyopathy, Transplant
Hypertension
Imaging Techniques, Nuclear CT, MRI, Echo
Policy
Prevention
Cardiac Surgery, Anesthesia
Of Interest to All Tracks
